NEW YORK (GenomeWeb) – German cancer diagnostics firm New Oncology today announced the closing of a €5 million ($5.7 million) financing round.

New Oncology offers the next-generation sequencing-based NEO platform for molecular analysis of genetic mutations in patient samples to help clinicians select targeted therapies and identify potential clinical trial opportunities. The technology identifies mutations, gene fusions, amplifications, and indels for which there are approved drugs or experimental substances in clinical testing.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Direct-to-consumer genetic testing companies have offered to test families separated at the southern US border, but that raises ethical issues.

CNBC reports that confirming a positive result from 23andMe's BRCA health report can be expensive.

The New York Times reports on a project to develop a tree DNA database to uncover illegal logging.

In PLOS this week: links between gut microbiome and colorectal cancer mutations, targeted sequencing uncovers genetic susceptibilities to epilepsy in Koreans, and more.